cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Murdani Abdullah
Contact Email
ina.jghe@gmail.com
Phone
+6285891498517
Journal Mail Official
ina.jghe@gmail.com
Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia
Location
Kota adm. jakarta pusat,
Dki jakarta
INDONESIA
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Published by The Indonesian Society for Digestive Endoscopy
ISSN : 14114801     EISSN : 23028181     DOI : -
Core Subject : Health,
Medicine & Pharmacology
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy is an academic journal which has been published since 2000 and owned by 3 Societies: The Indonesian Society of Gastroenterology; Indonesian Association for the Study of the Liver; The Indonesian Society for Digestive Endoscopy. The aim of our journal is to advance knowledge in Gastroenterology, Hepatology, and Digestive Endoscopy fields. We welcome authors for original articles, review articles, and case reports in the fields of Gastroenterology, Hepatology, and Digestive Endoscopy.
Arjuna Subject : Kedokteran - Ilmu Pencernaan
Articles 785 Documents
 75   76   77   78   79 
Recurrent Variceal Bleeding Due to Non-Cirrhotic Portal Hypertension in a Patient with Primary Myelofibrosis: Case Report Sitorus, Debora; Anwar, Bariani; Dinakrisma, Anastasia Asylia
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 26, No 3 (2025): VOLUME 26, NUMBER 3, December, 2025
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2632025293-297

Abstract

Acute upper gastrointestinal bleeding may arise from variceal or non-variceal sources. Primary myelofibrosis, classified as a subtype of myeloproliferative neoplasms, represents an uncommon clinically significant etiology of non-cirrhotic portal hypertension. The authors reported a case of a 39-year-old woman with recurrent variceal bleeding for six years. She presented with progressive weight loss, splenomegaly, and severe anemia. One year before her first episode of hematemesis, a bone marrow biopsy revealed myelofibrosis grade 2, and JAK2 V617F mutation was positive, confirming primary myelofibrosis. The treatment was discontinued due to high expense. Abdominal ultrasonography showed portal hypertension and changes suggestive of cirrhosis. She underwent successful endoscopic variceal ligation to control active bleeding, and initiation of a JAK inhibitor (ruxolitinib) was recommended for outpatient management to address the underlying disease. This case highlights that in patients presenting with variceal bleeding and portal hypertension in the absence of cirrhosis, myeloproliferative neoplasms, such as primary myelofibrosis should be considered as a differential diagnosis. This study aimed to raise awareness of primary myelofibrosis as a rare cause of non-cirrhotic portal hypertension and emphasize the importance of early recognition and targeted therapy to prevent recurrent bleeding and disease progression.
Validity and Reliability of the Indonesian Short Form-Leeds Dyspepsia Questionnaire (SF-LDQ) Prasetya, Ignatius Bima; Anas, Desriyadi; Al-Idrus, Syarifah Nur E’zzati; Simatupang, Flouria Stefanny; Herardi, Ryan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 26, No 3 (2025): VOLUME 26, NUMBER 3, December, 2025
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2632025212-218

Abstract

Background: The severity of dyspepsia symptoms is often overlooked despite established definitions and diagnostic criteria. The Short Form-Leeds Dyspepsia Questionnaire (SF-LDQ) is a validated English-language tool designed to evaluate these symptoms. This research focuses on creating and validating an Indonesian version of the SF-LDQ.Methods: The SF-LDQ was translated into Indonesian following standard procedures, including forward-backward translation, cross-checking, and pilot testing. Unselected patients from Dabo Regional Hospital and Dabo Lama Community Health Center (Pusat Kesehatan Masyarakat, or Puskesmas) completed a questionnaire upon enrollment and again after three days via direct follow-up or blinded phone interviews. Reliability was measured through internal consistency (Cronbach’s α) and test-retest analysis (Spearman’s correlation). Meanwhile, validity was evaluated by comparing SF-LDQ scores with Rome IV Criteria-based diagnoses from blinded physicians and analyzing diagnostic performance with ROC curves.Results: A total of 204 participants were included. The Indonesian SF-LDQ exhibited excellent reliability, with Cronbach’s α of 0.875 and Spearman’s correlation of 0.984 (p 0.001). Validity analysis demonstrated an AUC of 0.946 (p 0.001, 95% CI = 0.913–0.978). A cut-off score of 6.5 yielded 87.0% sensitivity and 93.3% specificity.Conclusion: The Indonesian SF-LDQ is a dependable and valid tool for evaluating the frequency and severity of dyspeptic symptoms.
Comparison of Quality of Life in Chronic Liver Disease Patients Based on Indonesian Version of SF-36 Questionnaire Mustika, Syifa; Nuri, Sofia; Jauza, Nadia Alfiani; F, Sri Lestari; Nugroho, Rama Tiar; Kalal, Chetan Ramesh
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 26, No 3 (2025): VOLUME 26, NUMBER 3, December, 2025
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2632025255-262

Abstract

Background: Liver cirrhosis is a chronic progressive disease associated with substantial morbidity and mortality. Although clinical management often emphasizes physical outcomes, assessment of health-related quality of life (HRQoL) provides a more comprehensive evaluation of patient well-being. A validated multidimensional instrument for HRQoL assessment is SF-36 (36-Item Short Form Health Survey). Therefore, this study aims to compare HRQoL among patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) using Indonesian version of SF-36. There are limited data from Indonesia comparing HRQoL across different stages of chronic liver disease, particularly including patients with chronic hepatitis.Methods: A cross-sectional study was conducted at Gastroenterohepatology Clinic of Saiful Anwar General Hospital, Malang, using 273 patients including 156 with chronic hepatitis, 88 with liver cirrhosis, and 29 with HCC. HRQoL was assessed using SF-36 questionnaire, which evaluated eight domains. Data were analyzed through Kruskal–Wallis test followed by Mann–Whitney post hoc analysis.Results: The results showed that HRQoL differed significantly across all SF-36 domains among the three groups (p 0.001), with the lowest scores observed in patients with HCC. Post hoc analysis showed a progressive decline in quality of life with increasing disease severity. However, no significant difference was found between cirrhosis and HCC groups in role limitations due to emotional problems (p 0.05).Conclusion: Advanced stages of chronic liver disease are associated with poorer HRQoL. Emotional role limitations appear less dependent on disease severity, signifying the need for psychological support across all stages.
Thrombospondin-2 as a Biomarker of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Budyono, Catarina; Ahda, Fatikha Rudia
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 26, No 3 (2025): VOLUME 26, NUMBER 3, December, 2025
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2632025263-267

Abstract

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is a highly prevalent liver disorder associated with obesity and metabolic syndrome, replacing the term Non-Alcoholic Fatty Liver Disease (NAFLD). The diagnosis of MAFLD is established based on the presence of hepatic steatosis accompanied by metabolic abnormalities such as overweight/obesity, type 2 diabetes mellitus, or metabolic dysregulation. Although liver biopsy remains the gold standard for diagnosis, its invasive nature underscores the need for practical, non-invasive biomarkers. This review aims to summarize the current evidence regarding thrombospondin-2 (TSP-2) as a potential biomarker of hepatic fibrosis in MAFLD. Recent data indicate that serum TSP-2 levels correlate with the severity of steatosis, inflammation, and fibrosis. TSP-2 also shows promise in distinguishing simple steatosis from steatohepatitis and in identifying patients at risk of advanced fibrosis. While these findings highlight the potential role of TSP-2 in diagnosis and disease monitoring, further clinical validation is required before its routine implementation in clinical practice.
Correlation of Neutrophil-Lymphocyte Ratio, Alpha-Fetoprotein, and PIVKA-II with Staging of HCC Related HBV at Dr. Mohammad Hoesin Hospital, Palembang Rahmayani, Febry; Suyata, Suyata; ., Legiran
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 26, No 3 (2025): VOLUME 26, NUMBER 3, December, 2025
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2632025219-227

Abstract

Background: The staging of Hepatocellular carcinoma (HCC) requires evaluating the tumor size and number, liver function, physical performance, tumor invasion, extrahepatic metastasis, and clinical symptoms. Biomarkers such as neutrophil-lymphocyte ratio (NLR), alpha-fetoprotein (AFP), and protein induced by the absence of vitamin K or antagonist-II (PIVKA-II) have been identified as valuable diagnostic and prognostic tools for HCC. This study aims to investigate the correlation between NLR, AFP, and PIVKA-II and HCC stages.Methods: This observational study was conducted at the Department of Internal Medicine, Dr. Mohammad Hoesin Hospital, Palembang, from April to July 2024. HCC stages were classified using the Barcelona Clinic Liver Cancer (BCLC) system. NLR, AFP, and PIVKA-II levels were measured using  ELISA method. Data were analyzed susing one-way ANOVA or the Kruskal-Wallis test.Results: A total of 38 patients with HCC who met the inclusion criteria were included in the study. There was a weak positive correlation between NLR and HCC stage (r = 0.334; p = 0.040), a moderate positive correlation between AFP and HCC stage (r = 0.499; p = 0.001), and a strong positive correlation between PIVKA-II and HCC stage (r = 0.797; p = 0.000). PIVKA-II and AFP were found to have a significant sequential effect on the BCLC stage.Conclusion: PIVKA-II and AFP are significant indicators for assessing BCLC stages, offering valuable support for the diagnosis and management of HCC.

Page 79 of 79 | Total Record : 785

 75   76   77   78   79 

Filter by Year

2000 2025


Reset
Filter By Issues
All Issue Vol 26, No 3 (2025): VOLUME 26, NUMBER 3, December, 2025 Vol 26, No 2 (2025): VOLUME 26, NUMBER 2, August, 2025 Vol 26, No 1 (2025): VOLUME 26, NUMBER 1, April, 2025 Vol 25, No 3 (2024): VOLUME 25, NUMBER 3, December, 2024 Vol 25, No 2 (2024): VOLUME 25, NUMBER 2, August, 2024 Vol 25, No 1 (2024): VOLUME 25, NUMBER 1, April, 2024 Vol 24, No 3 (2023): VOLUME 24, NUMBER 3, December, 2023 Vol 24, No 2 (2023): VOLUME 24, NUMBER 2, August, 2023 Vol 24, No 1 (2023): VOLUME 24, NUMBER 1, April, 2023 Vol 23, No 3 (2022): VOLUME 23, NUMBER 3, December 2022 Vol 23, No 2 (2022): VOLUME 23, NUMBER 2, August 2022 Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022 Vol 22, No 3 (2021): VOLUME 22, NUMBER 3, December 2021 Vol 22, No 2 (2021): VOLUME 22, NUMBER 2, August 2021 Vol 22, No 1 (2021): VOLUME 22, NUMBER 1, April 2021 Vol 21, No 3 (2020): VOLUME 21, NUMBER 3, December 2020 Vol 21, No 2 (2020): VOLUME 21, NUMBER 2, August 2020 Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020 Vol 20, No 3 (2019): VOLUME 20, NUMBER 3, December 2019 Vol 20, No 2 (2019): VOLUME 20, NUMBER 2, August 2019 Vol 20, No 1 (2019): VOLUME 20, NUMBER 1, April 2019 Vol 19, No 3 (2018): VOLUME 19, NUMBER 3, December 2018 Vol 19, No 2 (2018): VOLUME 19, NUMBER 2, August 2018 Vol 19, No 1 (2018): VOLUME 19, NUMBER 1, April 2018 Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017 Vol 18, No 2 (2017): VOLUME 18, NUMBER 2, AUGUST 2017 Vol 18, No 1 (2017): VOLUME 18, NUMBER 1, April 2017 Vol 17, No 3 (2016): VOLUME 17, NUMBER 3, December 2016 Vol 17, No 2 (2016): VOLUME 17, NUMBER 2, August 2016 Vol 17, No 1 (2016): VOLUME 17, NUMBER 1, April 2016 Vol 16, No 3 (2015): VOLUME 16, NUMBER 3, December 2015 Vol 16, No 2 (2015): VOLUME 16, NUMBER 2, August 2015 Vol 16, No 1 (2015): VOLUME 16, NUMBER 1, April 2015 Vol 15, No 3 (2014): VOLUME 15, NUMBER 3, December 2014 Vol 15, No 2 (2014): VOLUME 15, NUMBER 2, August 2014 Vol 15, No 1 (2014): VOLUME 15, NUMBER 1, April 2014 VOLUME 14, NUMBER 3, December 2013 VOLUME 14, NUMBER 2, August 2013 VOLUME 14, NUMBER 1, April 2013 VOLUME 13, NUMBER 3, Desember 2012 VOLUME 13, NUMBER 2, August 2012 VOLUME 13, NUMBER 1, April 2012 VOLUME 12, NUMBER 3, December 2011 VOLUME 12, NUMBER 2, August 2011 VOLUME 12, NUMBER 1, April 2011 VOLUME 11, NUMBER 3, December 2010 VOLUME 11, NUMBER 2, August 2010 VOLUME 11, NUMBER 1, April 2010 VOLUME 10, NUMBER 3, December 2009 VOLUME 10, ISSUE 2, August 2009 VOLUME 10, ISSUE 1, April 2009 VOLUME 9, ISSUE 3, December 2008 VOLUME 9, ISSUE 2, August 2008 VOLUME 9, ISSUE 1, April 2008 VOLUME 8, ISSUE 3, December 2007 VOLUME 8 ISSUE 2 August 2007 VOLUME 8, ISSUE 1, April 2007 VOLUME 7, ISSUE 3, December 2006 VOLUME 7, ISSUE 2, August 2006 VOLUME 7, ISSUE 1, April 2006 VOLUME 6, ISSUE 3, December 2005 VOLUME 6, ISSUE 2, August 2005 VOLUME 6, ISSUE 1, April 2005 VOLUME 5, ISSUE 3, December 2004 VOLUME 5, ISSUE 2, August 2004 VOLUME 5, ISSUE 1, April 2004 VOLUME 4, ISSUE 3, December 2003 VOLUME 4, ISSUE 2, August 2003 VOLUME 4, NUMBER 1, April 2003 VOLUME 3, NUMBER 3, December 2002 VOLUME 3, NUMBER 2, August 2002 VOLUME 3, NUMBER 1, April 2002 VOLUME 2, NUMBER 3, December 2001 VOLUME 2, NUMBER 2, August 2001 VOLUME 2, NUMBER 1, April 2001 VOLUME 1, NUMBER 1, December 2000 More Issue